Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells

On May 16, at the ASTM International May Committee Meeting in Denver, Colorado, Massachusetts stem cell biotechnology company Asymmetrex received unanimous approval of its proposal for an interlaboratory evaluation of the company’s AlphaSTEM Test™ technology for counting therapeutic adult tissue stem cells. Highlighting the importance of the approval, a day earlier, the Standards Coordinating Body

May 21, 2019

Asymmetrex Presents Proposal for ASTM Interlaboratory Evaluation of AlphaSTEM Test™ Technology Towards Establishing A Standard for Counting Therapeutic Stem Cells

Today, May 16, at the ASTM International May Committee Meeting in Denver, Colorado, Massachusetts stem cell biotechnology company Asymmetrex will present a proposal for an interlaboratory evaluation of the company’s AlphaSTEM Test™. Approval of this ASTM evaluation will be an important step in Asymmetrex’s plan to establish the AlphaSTEM Test™ as a stem cell industry

May 16, 2019

Asymmetrex Visits World Drug Safety Congress 2019

Tuesday in Philadelphia, at the World Drug Safety Congress 2019 (April 16-17), Asymmetrex introduces its AlphaSTEM Test™ to the international pharmaceutical community.  By early detection of drug candidates that are stem cell-toxic, Asymmetrex can eliminate drugs that will fail late after great cost because they induce chronic organ failure.  By assaying for toxic effects on

April 15, 2019

Asymmetrex Article on p53 and CRISPR/Cas9 is Among CRISPR Journal’s ‘Articles Everyone is Talking About’

This week The CRISPR Journal released the articles that people are talking about, and Asymmetrex’s article on p53 and CRISPR/Cas9 made the list. This article is free to read until February 7, 2019. “I wish to suggest another explanation for the worrisome observations based on often overlooked properties of p53 as a regulator of postnatal

January 31, 2019

Asymmetrex Writes Article for Parent’s Guide to Cord Blood

Now in its fifth month, Massachusetts stem cell biotechnology company Asymmetrex continues its campaign to increase awareness of the adult tissue stem cell counting problem in stem cell medicine. Now targeting patients and patient advocacy groups, for the month of January, the company’s director is featured on the Parents’ Guide to Cord Blood website with

January 16, 2019

Asymmetrex Publishes Chapter Explaining the Critical Need for Stem Cell Dosing

Since September 2018, Massachusetts stem cell biotechnology company Asymmetrex has been pursuing a campaign to increase awareness of the adult tissue stem cell counting problem in stem cell medicine and the stem cell supply industry. The latest 2018 installment in this effort is a book chapter, authored by Asymmetrex’s founder and director, that illuminates why

January 10, 2019

Asymmetrex Intensifies Campaign to Increase Awareness of the Adult Tissue Stem Cell Counting Problem

Since September of this year, stem cell biotechnology company Asymmetrex has been leading a campaign to increase awareness of the adult tissue stem cell counting problem in stem cell medicine and the stem cell supply industry. During the month of November, the company is intensifying this effort with new educational publications and presentations at clinical

November 7, 2018

Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies

Four months ago, alarms were set off by two reports showing that CRISPR-Cas9 gene editing of non-transformed human cells occurred with a high frequency of carcinogenic mutations in the p53 cancer gene. Though some experts worried that there would be no easy solution to this problem, published in today’s October issue of The CRISPR Journal,

October 18, 2018

Asymmetrex Increases Awareness on The Stem Cell Counting Problem

True or False for Stem Cell Awareness Day 2018 is an excellent and needed RegMedNet feature.  There are many misconceptions about stem cells in the research space, and even more misinformation or lacking information in the stem cell industrial space.  These sometimes surprising deficits in knowledge and understanding inhibit progress in stem cell medicine  and stem cell commercial

October 11, 2018

Asymmetrex Starts New Campaign for Greater Awareness of the Importance of Counting Tissue Stem Cells

Now that Massachusetts stem cell biotechnology company Asymmetrex has developed the first and only technology for specific and accurate counting of therapeutic tissue stem cells, today the company has launched a campaign to alert stem cell scientists, physicians, and patients to the long unmet need of a means to count tissue stem cells. The major

September 13, 2018

Next Page »